- CEO
- Hang-Myung Lee
- Full Time Employees
- 532
- Sector
- Health technology
- Industry
- Pharmaceuticals: other
- Address
- Hwaseong-si South Korea
- IPO Date
- Oct 1, 2025
- Business
- Myung In Pharm Co., Ltd. engages in the research, development, manufacturing, and commercialization of ethical pharmaceuticals, over-the-counter medications, active pharmaceutical ingredients, and specialized formulation products in South Korea and internationally. Founded in 1985 and headquartered in Seoul, South Korea, with major manufacturing and research facilities located in Hwaseong-si, Gyeonggi-do, the company operates as a market leader in central nervous system therapeutics while serving hospitals, clinics, pharmacies, and wholesale distributors.
The company's primary business activities are structured around prescription pharmaceuticals, consumer health products, chemical synthesis, and contract manufacturing. Its ethical drug portfolio specializes in central nervous system (CNS) treatments, including antipsychotics such as Rispen, Neurozapin, Lepizol, and Q-Rokel for schizophrenia and bipolar disorders; antidepressants and mood stabilizers such as Newpram and Fluctin; anticonvulsants such as Q-Pam for epilepsy; and cognitive and neurodegenerative therapies such as Silvercept for dementia and Alzheimer's disease, alongside specialized medications for Parkinson's disease, insomnia, and attention deficit hyperactivity disorder. Beyond CNS treatments, the company manufactures cardiovascular agents, including antihypertensive, antithrombotic, antiplatelet, and antianginal formulations; gastrointestinal medications; anti-inflammatory and analgesic drugs; and respiratory agents. Its over-the-counter (OTC) division produces consumer health brands, notably Igatan for periodontal gum care and Mayqueen Q for constipation relief. In addition, the company operates an integrated active pharmaceutical ingredient (API) synthesis division that develops and manufactures high-purity chemical substances for internal formulation and commercial supply, as well as contract development and manufacturing organization (CDMO) services specializing in advanced pellet formulations.
In recent developments, Myung In Pharm completed its initial public offering and listed its common shares on the Korea Exchange under ticker 317450 to accelerate international expansion and strengthen corporate governance. The company broadened its advanced neuropsychiatry pipeline by securing an exclusive license, development, and commercialization agreement with Italy-based Newron Pharmaceuticals for evenamide, an orally administered new chemical entity for schizophrenia, and joined the international Phase III ENIGMA-TRS clinical program following regulatory approval in South Korea. Furthermore, the company expanded its neurological pipeline through the in-licensing of Paxroyah (P2B001) for Parkinson's disease and constructed dedicated large-scale pellet production facilities at its Baran manufacturing campus in Hwaseong to scale its CDMO business while pursuing global regulatory certifications across major international markets.